Cushing's Syndrome: Tirzepatide
The question
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of prescribing Mounjaro for Cushing's syndrome on the NHS.
Answered by Karin Smyth
The Department has made no assessment. Mounjaro is not licensed as a treatment option for Cushing’s syndrome. The National Institute for Health and Care Excellence (NICE) would consider an evaluation of Mounjaro for Cushing’s syndrome if the company, Eli Lilly, were to apply to the Medicines and Healthcare products Regulatory Agency for a marketing authorisation, or licence, for use in the treatment of Cushing’s syndrome.
Clinicians can prescribe medicines outside of their licensed indication, known as “off-label” use, where there is sufficient evidence and/or experience of using the medicine to show its safety, quality, and efficacy, provided there is no suitable alternative licensed medicine, and subject to funding by the National Health Service locally.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →